No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Sunshine Novartis (688621.SH): has cumulatively repurchased 2.43% of the company's shares.
On March 4, Guangming Nuohe (688621.SH) announced that as of February 28, 2025, the company has cumulatively repurchased 2,716,789 shares through centralized bidding, accounting for 2.43% of the current total share capital of 112,000,000 shares. The highest purchase price was 45.60 yuan/share and the lowest was 34.05 yuan/share, with a total amount paid of 99,748,373.17 yuan (excluding stamp duty, transaction commission, and other transaction costs).
Sunshine Novo: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
Sunshine Novo (688621.SH): The net income for the year 2024 is 0.18 billion yuan, a year-on-year decrease of 2.42%.
Gelonghui, on February 27, reported that Sunshine Novo (688621.SH) announced the performance summary for the year 2024. During the reporting period, the company achieved revenue of 1,077.7245 million yuan, a year-on-year increase of 15.62%; the net income attributable to shareholders of the parent company was 180.2892 million yuan, a year-on-year decrease of 2.42%; the net income attributable to shareholders of the parent company after deducting non-recurring gains and losses was 168.1701 million yuan, a year-on-year decrease of 6.61%. During the reporting period, influenced by the centralized procurement policy and intensified market competition, the overall R&D demand in the domestic Biomedical industry experienced a certain decline.
Sunshine Nuohe (688621.SH) has signed a cooperation intention agreement with Huawei to jointly develop an AI peptide molecule large model platform based on Huawei's Pangu large model.
On February 21, Gluon Conference reported that Sunlight Novo (688621.SH) announced on the investor interaction platform that the company has signed a cooperation intention agreement with Huawei to jointly develop an AI peptide molecular large model platform based on Huawei's Pangu large model. Recently, both parties are discussing specific implementation terms and other details. After the formal agreement is signed, the company will promptly announce it in accordance with the Shanghai Stock Exchange's information disclosure requirements. Thank you for your attention and suggestions!